Related Experiment Video
Updated: Apr 5, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.4K
IL-20 in rheumatoid arthritis
Yu-Hsiang Hsu1, Ming-Shi Chang2
1Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.
Drug Discovery Today
|August 23, 2015
Summary
Interleukin-20 (IL-20) plays a key role in rheumatoid arthritis pathogenesis, driving joint inflammation and bone damage. Therapies targeting IL-20 are now in clinical trials for treating this autoimmune disease.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic joint inflammation and bone destruction.
- Interleukin-20 (IL-20) has been identified as a significant factor in the pathogenesis of rheumatoid arthritis.
- Research into IL-20 expression and regulation in this context has been ongoing since 2006.
Purpose of the Study:
- To review the current understanding of Interleukin-20's role in the development of rheumatoid arthritis.
- To consolidate knowledge on IL-20's involvement in the pathogenic mechanisms of rheumatoid arthritis.
Main Methods:
- Literature review focusing on studies published since 2006.
- Analysis of research on IL-20 expression, regulation, and function in rheumatoid arthritis models and patients.
Main Results:
- IL-20 is implicated in promoting chronic joint inflammation characteristic of rheumatoid arthritis.
- IL-20 contributes to the bone destruction observed in rheumatoid arthritis.
- Targeting IL-20 with antibodies has shown promise, leading to clinical trials.
Conclusions:
- Interleukin-20 is a critical mediator in rheumatoid arthritis pathogenesis.
- Blocking IL-20 represents a potential therapeutic strategy for rheumatoid arthritis.
- Further research into IL-20 pathways may yield novel treatment approaches.
Related Concept Videos
01:24T Cell Types and Functions
3.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K
01:20The JAK-STAT Signaling Pathway
14.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.0K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
685
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
685
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
759
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
759
01:29Autoimmune Disorders
2.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.2K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
650
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
650